HeartStation Selects iBASIS eSIM for Remote Monitoring of AEDs to Ensure They Are Fully Powered and Operational in the Event of an Emergency

Today iBASIS, a provider of communications solutions for operators and digital players worldwide, announced that HeartStation, a global manufacturer of Automated External Defibrillator (AED) cabinets and accessibility products, has selected iBASIS eSIM for remote monitoring of AEDs to ensure they are fully powered and operational in the event of an emergency.

iBASIS’ selection follows one of the fastest implementations of its IoT solution to date, with field trials completed in just five days in late December 2019 and solution installed as of January 2020.

As the U.S. National Safety Council reports, greater access to AEDs could save 40,000 lives each year in the U.S. alone, and access to fully powered AEDs by bystanders can increase the odds of survival up to 40% and higher.1 The iBASIS eSIM enables dynamic monitoring of AEDs via an eSIM card installed within the AED cabinet. A signal is regularly monitored during the AED self-test, with automatic alerts to dispatch a technician should the device not meet the necessary operation.

Over 50,000 HeartStation AED units will be globally, remotely monitored via the iBASIS eSIM. The iBASIS solution is differentiated in its ability to enable dynamic routing selection of communications carrier in the cloud to drive the most effective network connectivity to remotely monitor and manage devices worldwide.

“The iBASIS eSIM is the perfect solution to further enhance the effectiveness of critical public access defibrillation programs by enabling remote monitoring of AEDs,” says Keith Hochhalter, President, HeartStation. “This solution ensures that devices will be fully available in critical circumstances, and we are very proud to partner with a company that shares our commitment to delivering life-changing innovation and performance.”

“HeartStation has developed unsurpassed capabilities for enhancing access to lifesaving devices,” says Ajay CTO, iBASIS. “We are extremely pleased to partner with them to deliver the remote monitoring needed to ensure their devices are always powered. We are also very happy with the incredible speed with which the teams have implemented the iBASIS eSIM capability. Our work with HeartStation reflects our commitment to enabling companies around the world to rapidly achieve the highest performance in management and monitoring of their products globally.”


Reference

1 Source: US National Safety Council

SourceiBASIS

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”